

Chapter 134

Systemic Autoinflammatory Diseases

Chyi-Chia Richard Lee &
Raphaella Goldbach-Mansky

REFERENCES

1. Kastner DL, Aksentijevich I, Goldbach-Mansky R: Autoinflammatory disease reloaded: A clinical perspective. *Cell* **140**(6):784-790, 2010
2. The International FMF Consortium: Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. *Cell* **90**(4):797-807, 1997
3. French FMF Consortium: A candidate gene for familial Mediterranean fever. *Nat Genet* **17**(1):25-31, 1997
4. McDermott MF et al: Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. *Cell* **97**(1):133-144, 1999
5. Houten SM et al: Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. *Nat Genet* **22**(2):175-177, 1999
6. Drenth JP et al: Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. *Nat Genet* **22**(2):178-181, 1999
7. Miceli-Richard C et al: CARD15 mutations in Blau syndrome. *Nat Genet* **29**(1):19-20, 2001
8. Kanazawa N et al: Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: Common genetic etiology with Blau syndrome. *Blood* **105**(3):1195-1197, 2005
9. Wise CA et al: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. *Hum Mol Genet* **11**(8):961-969, 2002
10. Hoffman HM et al: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. *Nat Genet* **29**(3):301-305, 2001
11. Feldmann J et al: Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. *Am J Hum Genet* **71**(1):198-203, 2002
12. Aksentijevich I et al: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. *Arthritis Rheum* **46**(12):3340-3348, 2002
13. Goldbach-Mansky R: Blocking interleukin-1 in rheumatic diseases. *Ann N Y Acad Sci* **1182**:111-123, 2009
14. Aksentijevich I et al: An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. *N Engl J Med* **360**(23):2426-2437, 2009
15. Reddy S et al: An autoinflammatory disease due to homozygous deletion of the IL1RN locus. *N Engl J Med* **360**(23):2438-2444, 2009
16. Ferguson PJ et al: Homozygous mutations in LPIN2 are responsible for the syndrome of chronic recurrent multifocal osteomyelitis and congenital dyserythropoietic anaemia (Majeed syndrome). *J Med Genet* **42**(7):551-557, 2005
17. Ferguson PJ, El-Shanti HI: Autoinflammatory bone disorders. *Curr Opin Rheumatol* **19**(5):492-498, 2007
18. Glocker EO et al: Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. *N Engl J Med* **361**(21):2033-2045, 2009
19. Medzhitov R: Recognition of microorganisms and activation of the immune response. *Nature* **449**(7164):819-826, 2007
20. Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. *Nat Immunol* **11**(5):373-384, 2010
21. Schroder K, Tschopp J: The inflammasomes. *Cell* **140**(6):821-832, 2010
22. Masters SL et al: Horror autoinflammaticus: The molecular pathophysiology of autoinflammatory disease (*). *Annu Rev Immunol* **27**:621-668, 2009

23. McGonagle D et al: Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. *Ann Rheum Dis* **66**(12):1683-1684, 2007
24. So A et al: A pilot study of IL-1 inhibition by anakinra in acute gout. *Arthritis Res Ther* **9**(2):R28, 2007
25. Terkeltaub R et al: The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. *Ann Rheum Dis* **68**(10):1613-1617, 2009
26. Larsen CM et al: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *N Engl J Med* **356**(15):1517-1526, 2007
27. Botsios C et al: Resistant Behcet disease responsive to anakinra. *Ann Intern Med* **149**(4):284-286, 2008
28. Pascual V et al: Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. *J Exp Med* **201**(9):1479-1486, 2005
29. RLaRHA K: A case of cold urticaria with an unusual family history. *JAMA* **114**:1067-1068, 1940
30. Muckle TJ: The 'Muckle-Wells' syndrome. *Br J Dermatol* **100**(1):87-92, 1979
31. Prieur AM, Griscelli C: Arthropathy with eruption, chronic meningitis, eye lesions, and mental retardation. *J Pediatr* **99**(1):79-83, 1981
32. Martinon F, Burns K, Tschopp J: The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. *Mol Cell* **10**(2):417-426, 2002
33. Gattorno M et al: Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. *Arthritis Rheum* **56**(9):3138-3148, 2007
34. Lachmann HJ et al: In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. *J Exp Med* **206**(5):1029-1036, 2009
35. Goldbach-Mansky R et al: Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. *N Engl J Med* **355**(6):581-592, 2006
36. Aksentijevich I et al: The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. *Arthritis Rheum* **56**(4):1273-1285, 2007
37. Saito M et al: Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum* **52**(11):3579-3585, 2005
38. Hill SC et al: Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). *Pediatr Radiol* **37**(2):145-152, 2007
39. Johnstone RF, Dolen WK, Hoffman HM: A large kindred with familial cold autoinflammatory syndrome. *Ann Allergy Asthma Immunol* **90**(2):233-237, 2003
40. Tindall JP, Beeker SK, Rosse WF: Familial cold urticaria. A generalized reaction involving leukocytosis. *Arch Intern Med* **124**(2):129-134, 1969
41. Farasat S, Aksentijevich I, Toro JR: Autoinflammatory diseases: Clinical and genetic advances. *Arch Dermatol* **144**(3):392-402, 2008
42. Hoffman HM, Wanderer AA, Broide DH: Familial cold autoinflammatory syndrome: Phenotype and genotype of an autosomal dominant periodic fever. *J Allergy Clin Immunol* **108**(4):615-620, 2001
43. Lieberman A, Grossman ME, Silvers DN: Muckle-Wells syndrome: Case report and review of cutaneous pathology. *J Am Acad Dermatol* **39**(2 Pt 1):290-291, 1998
44. Zip CM et al: Familial cold urticaria. *Clin Exp Dermatol* **18**(4):338-341, 1993
45. Aganna E et al: Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. *Arthritis Rheum* **46**(9):2445-2452, 2002
46. Thornton BD et al: Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. *Am J Kidney Dis* **49**(3):477-481, 2007
47. Neven B, Prieur AM, Quartier dit Maire P: Cryopyrinopathies: Update on pathogenesis and treatment. *Nat Clin Pract Rheumatol* **4**(9):481-489, 2008
48. Hoffman HM et al: Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. *Arthritis Rheum* **58**(8):2443-2452, 2008
49. Lachmann HJ et al: Use of canakinumab in the cryopyrin-associated periodic syndrome. *N Engl J Med* **360**(23):2416-2425, 2009
50. Neven B et al: Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory

- disease/chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum* **62**(1):258-267, 2010
51. Gensure RC et al: A novel COL1A1 mutation in infantile cortical hyperostosis (Caffey disease) expands the spectrum of collagen-related disorders. *J Clin Invest* **115**(5):1250-1257, 2005
 52. Leung VC, Lee KE: Infantile cortical hyperostosis with intramedullary lesions. *J Pediatr Orthop* **5**(3):354-357, 1985
 53. Ivker RA et al: Infantile generalized pustular psoriasis associated with lytic lesions of the bone. *Pediatr Dermatol* **10**(3):277-282, 1993
 54. Touitou I: The spectrum of Familial Mediterranean Fever (FMF) mutations. *Eur J Hum Genet* **9**(7):473-183, 2001
 55. Majeed HA et al: Familial Mediterranean fever in children: The expanded clinical profile. *Q J Med* **92**(6):309-318, 1999
 56. Tunca M et al: Familial Mediterranean fever (FMF) in Turkey: Results of a nationwide multicenter study. *Medicine (Baltimore)* **84**(1):1-11, 2005
 57. Stoffman N et al: Higher than expected carrier rates for familial Mediterranean fever in various Jewish ethnic groups. *Eur J Hum Genet* **8**(4):307-310, 2000
 58. Tunca M et al: The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. *Eur J Hum Genet* **10**(12):786-789, 2002
 59. Yilmaz E et al: Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. *Eur J Hum Genet* **9**(7):553-555, 2001
 60. Chae JJ et al: Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. *Mol Cell* **11**(3):591-604, 2003
 61. Booth DR et al: The genetic basis of autosomal dominant familial Mediterranean fever. *Q J Med* **93**(4):217-221, 2000
 62. Bernot A et al: Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). *Hum Mol Genet* **7**(8):1317-1325, 1998
 63. Aksentijevich I et al: Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. *Am J Hum Genet* **64**(4):949-962, 1999
 64. Dode C et al: Mutations in the MEFV gene in a large series of patients with a clinical diagnosis of familial Mediterranean fever. *Am J Med Genet* **92**(4):241-246, 2000
 65. La Regina M et al: Familial Mediterranean fever is no longer a rare disease in Italy. *Eur J Hum Genet* **11**(1):50-56, 2003
 66. Aldea A et al: The west side story: MEFV haplotype in Spanish FMF patients and controls, and evidence of high LD and a recombination "hot-spot" at the MEFV locus. *Hum Mutat* **23**(4):399, 2004
 67. Konstantopoulos K, Kanta A: Familial Mediterranean fever seems to be not uncommon in Greece. *Eur J Hum Genet* **12**(2):85-86, 2004
 68. Deltas CC et al: Familial Mediterranean fever (FMF) mutations occur frequently in the Greek-Cypriot population of Cyprus. *Genet Test* **6**(1):15-21, 2002
 69. Sohar E et al: Familial Mediterranean fever. A survey of 470 cases and review of the literature. *Am J Med* **43**(2):227-253, 1967
 70. Schwabe AD, Peters RS: Familial Mediterranean fever in armenians. analysis of 100 cases. *Medicine (Baltimore)* **53**(6):453-462, 1974
 71. Marek-Yagel D et al: Clinical disease among patients heterozygous for familial Mediterranean fever. *Arthritis Rheum* **60**(6):1862-1866, 2009
 72. Booty MG et al: Familial Mediterranean fever with a single MEFV mutation: Where is the second hit? *Arthritis Rheum* **60**(6):1851-1861, 2009
 73. James LC et al: Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. *Proc Natl Acad Sci U S A* **104**(15):6200-6205, 2007
 74. Song B et al: Retrovirus restriction by TRIM5alpha variants from Old World and New World primates. *J Virol* **79**(7):3930-3937, 2005
 75. Perron MJ, Stremlau M, Sodroski J: Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. *J Virol* **80**(11):5631-5636, 2006
 76. Schaner P et al: Episodic evolution of pyrin in primates: Human mutations recapitulate ancestral amino acid states. *Nat Genet* **27**(3):318-321, 2001
 77. Centol M, Aksentijevich I, Kastner DL: The hereditary periodic fever syndromes: Molecular analysis of a new family of inflammatory diseases. *Hum Mol Genet* **7**(10):1581-1588, 1998

78. Chae JJ et al: The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. *Blood* **112**(5):1794-1803, 2008
79. Mansfield E et al: The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. *Blood* **98**(3):851-859, 2001
80. Goldfinger SE: Colchicine for familial Mediterranean fever. *N Engl J Med* **287**(25):1302
81. Chae JJ et al: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. *Proc Natl Acad Sci U S A* **103**(26):9982-9987, 2006
82. Yu JW et al: Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. *Mol Cell* **28**(2):214-227, 2007
83. Richards N et al: Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. *J Biol Chem* **276**(42):39320-39329, 2001
84. Padeh S et al: Familial Mediterranean Fever in the first two years of life: A unique phenotype of disease in evolution. *J Pediatr* **156**(6):985-989, 2010
85. Zimand S et al: Familial Mediterranean fever presenting with massive cardiac tamponade. *Clin Exp Rheumatol* **12**(1):67-69, 1994
86. Kees S et al: Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). *Q J Med* **90**(10):643-647, 1997
87. Langevitz P et al: Protracted febrile myalgia in patients with familial Mediterranean fever. *J Rheumatol* **21**(9):1708-1709, 1994
88. Livneh A et al: Recurrent episodes of acute scrotum with ischemic testicular necrosis in a patient with familial Mediterranean fever. *J Urol* **151**(2):431-432, 1994
89. Gedalia A, Zamir S: Neurologic manifestations in familial Mediterranean fever. *Pediatr Neurol* **9**(4):301-302, 1993
90. Barzilai A et al: Erysipelas-like erythema of familial Mediterranean fever: Clinicopathologic correlation. *J Am Acad Dermatol* **42**(5 Pt 1):791-795, 2000
91. Azizi E, Fisher BK: Cutaneous manifestations of familial Mediterranean fever. *Arch Dermatol* **112**(3):364-366, 1976
92. Majeed HA et al: The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. *Q J Med* **75**(278):607-616, 1990
93. Samuels J et al: Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. *Medicine (Baltimore)* **77**(4):268-297, 1998
94. Medlej-Hashim, M et al: Familial Mediterranean Fever: Association of elevated IgD plasma levels with specific MEFV mutations. *Eur J Hum Genet* **9**(11):849-854, 2001
95. Tunca M et al: Acute phase response and evolution of familial Mediterranean fever. *Lancet* **353**(9162):1415, 1999
96. Lachmann HJ et al: Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. *Rheumatology (Oxford)* **45**(6):746-750, 2006
97. Lachmann HJ et al: Natural history and outcome in systemic AA amyloidosis. *N Engl J Med* **356**(23):2361-2371, 2007
98. Livneh A et al: MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. *Amyloid* **6**(1):1-6, 1999
99. Saatci U et al: Familial Mediterranean fever and amyloidosis in children. *Acta Paediatr* **82**(8):705-706, 1993
100. Tinaztepe K et al: The association between Henoch-Schonlein syndrome and renal amyloidosis: A proposal of a pathogenic mechanism. *Turk J Pediatr* **35**(4):249-256, 1993
101. Reidpath DD, Allotey P: Infant mortality rate as an indicator of population health. *J Epidemiol Community Health* **57**(5):344-346, 2003
102. Touitou I et al: Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. *Arthritis Rheum* **56**(5):1706-1712, 2007
103. Baba S et al: A novel allelic variant of serum amyloid A, SAA1 gamma: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. *Hum Mol Genet* **4**(6):1083-1087, 1995
104. Booth DR et al: SAA1 alleles as risk factors in reactive systemic AA amyloidosis. *Amyloid* **5**(4):262-265, 1998
105. Wright DG et al: Efficacy of intermittent colchicine therapy in familial Mediterranean fever. *Ann Intern Med* **86**(2):162-165, 1977
106. Kone-Paut I et al: The clinical spectrum of 94 patients carrying a single mutated MEFV allele. *Rheumatology (Oxford)* **48**(7):840-842, 2009
107. Zemer D et al: A controlled trial of colchicine in preventing attacks of familial mediterranean fever. *N Engl J Med* **291**(18):932-934, 1974

108. Kuncl RW et al: Colchicine myopathy and neuropathy. *N Engl J Med* **316**(25):1562-1568, 1987
109. Drenth JP, van der Meer JW: Hereditary periodic fever. *N Engl J Med* **345**(24):1748-1757, 2001
110. Hoffmann G et al: Mevalonic aciduria—An inborn error of cholesterol and nonsterol isoprene biosynthesis. *N Engl J Med* **314**(25):1610-1614, 1986
111. Schafer BL et al: Molecular cloning of human mevalonate kinase and identification of a missense mutation in the genetic disease mevalonic aciduria. *J Biol Chem* **267**(19):13229-13238, 1992
112. Cuisset L et al: Molecular analysis of MVK mutations and enzymatic activity in hyper-IgD and periodic fever syndrome. *Eur J Hum Genet* **9**(4):260-266, 2001
113. van der Hilst JC et al: Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. *Medicine (Baltimore)* **87**(6):301-310, 2008
114. Houten SM et al: Carrier frequency of the V3771 (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. *Eur J Hum Genet* **11**(2):196-200, 2003
115. Hoffmann GF et al: Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. *Pediatrics* **91**(5):915-921, 1993
116. Hinson DD et al: Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry. *Am J Hum Genet* **65**(2):327-335, 1999
117. Houten SM et al: Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hyper-IgD and periodic fever syndrome. *Hum Mol Genet* **11**(25):3115-3124, 2002
118. McTaggart SJ: Isoprenylated proteins. *Cell Mol Life Sci* **63**(3):255-267, 2006
119. Frenkel J et al: Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. *Arthritis Rheum* **46**(10):2794-2803, 2002
120. Mandey SH et al: A role for geranylgeranylation in interleukin-1beta secretion. *Arthritis Rheum* **54**(11):3690-3695, 2006
121. Drenth JP, Haagsma CJ, van der Meer JW: Hyperimmunoglobulinemia D and periodic fever syndrome. The clinical spectrum in a series of 50 patients. International Hyper-IgD Study Group. *Medicine (Baltimore)* **73**(3):133-144, 1994
122. Drenth JP et al: Cutaneous manifestations and histologic findings in the hyperimmunoglobulinemia D syndrome. International Hyper IgD Study Group. *Arch Dermatol* **130**(1):59-65, 1994
123. Boom BW et al: IgD immune complex vasculitis in a patient with hyperimmunoglobulinemia D and periodic fever. *Arch Dermatol* **126**(12):1621-1624, 1990
124. Haraldsson A et al: Immunological studies in the hyper-immunoglobulin D syndrome. *J Clin Immunol* **12**(6):424-428, 1992
125. Miyagawa S et al: Association of hyperimmunoglobulinemia D syndrome with erythema elevatum diutinum. *Br J Dermatol* **128**(5):572-574, 1993
126. Hinson DD et al: Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. *Am J Med Genet* **78**(5):408-412, 1998
127. Simon A et al: Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. *Clin Pharmacol Ther* **75**(5):476-483, 2004
128. Neven B et al: Allogeneic bone marrow transplantation in mevalonic aciduria. *N Engl J Med* **356**(26):2700-2703, 2007
129. Lindor M et al: A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome. *Mayo Clin Proc* **72**(7):611-615, 1997
130. Shoham NG et al: Pypin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. *Proc Natl Acad Sci U S A* **100**(23):13501-13506, 2003
131. Yeon HB et al: Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q. *Am J Hum Genet* **66**(4):1443-1448, 2000
132. Stichweh DS, Punaro M, Pascual V: Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. *Pediatr Dermatol* **22**(3):262-265, 2005
133. Dierselhuis MP et al: Anakinra for flares of pyogenic arthritis in PAPA syndrome. *Rheumatology (Oxford)* **44**(3):406-408, 2005
134. Brenner M et al: Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. *Br J Dermatol* **161**(5):1199-1201, 2009
135. Hull K.M et al: The TNF receptor-associated periodic syndrome (TRAPS): Emerging concepts of an autoinflammatory disorder. *Medicine (Baltimore)* **81**(5):349-368, 2002

136. Lainka E et al: Incidence of TNFRSF1A mutations in German children: Epidemiological, clinical and genetic characteristics. *Rheumatology (Oxford)* **48**(8):987-991, 2009
137. Sarrauste de Menthiere C et al: INFEVERS: The Registry for FMF and hereditary inflammatory disorders mutations. *Nucleic Acids Res* **31**(1):282-285, 2003
138. Touitou I et al: Infevers: An evolving mutation database for auto-inflammatory syndromes. *Hum Mutat* **24**(3):194-198, 2004
139. Milhavel F et al: The infevers autoinflammatory mutation online registry: Update with new genes and functions. *Hum Mutat* **29**(6):803-808, 2008
140. Banner DW et al: Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation. *Cell* **73**(3):431-445, 1993
141. Hull KM et al: The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. *Curr Opin Rheumatol* **15**(1):61-69, 2003
142. Ravet N et al: Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. *Ann Rheum Dis* **65**(9):1158-1162, 2006
143. Aksentijevich I et al: The tumor-necrosis-factor receptor-associated periodic syndrome: New mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. *Am J Hum Genet* **69**(2):301-314, 2001
144. Aganna E et al: Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. *Arthritis Rheum* **48**(9):2632-2644, 2003
145. Lobito AA et al: Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). *Blood* **108**(4):1320-1327, 2006
146. Todd I et al: Mutant tumor necrosis factor receptor associated with tumor necrosis factor receptor-associated periodic syndrome is altered antigenically and is retained within patients' leukocytes. *Arthritis Rheum* **56**(8):2765-2773, 2007
147. Simon A et al: Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. *Proc Natl Acad Sci U S A* **107**(21):9801-9806, 2010
148. Jacobelli S et al: Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). *Rheumatology (Oxford)* **46**(7):1211-1212, 2007
149. Nedjai B et al: Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum* **58**(1):273-283, 2008
150. Nedjai B et al: Proinflammatory action of the anti-inflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum* **60**(2):619-625, 2009
151. Stjernberg-Salmela S et al: Low TNF-induced NF-kappaB and p38 phosphorylation levels in leucocytes in tumour necrosis factor receptor-associated periodic syndrome. *Rheumatology (Oxford)* **49**(2):382-390, 2010
152. Toro JR et al: Tumor necrosis factor receptor-associated periodic syndrome: A novel syndrome with cutaneous manifestations. *Arch Dermatol* **136**(12):1487-1494, 2000
153. Nakamura M, Kobayashi M, Tokura Y: A novel missense mutation in tumour necrosis factor receptor superfamily 1A (TNFRSF1A) gene found in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) manifesting adult-onset Still disease-like skin eruptions: Report of a case and review of the Japanese patients. *Br J Dermatol* **161**(4):968-970, 2009
154. Hull K.M et al: Monocytic fasciitis: A newly recognized clinical feature of tumor necrosis factor receptor dysfunction. *Arthritis Rheum* **46**(8):2189-2194, 2002
155. Galon J et al: TNFRSF1A mutations and auto-inflammatory syndromes. *Curr Opin Immunol* **12**(4):479-486, 2000
156. Drewe E et al: Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. *Rheumatology (Oxford)* **42**(2):235-239, 2003
157. Weyhreter H et al: A new mutation causing autosomal dominant periodic fever syndrome in a Danish family. *J Pediatr* **142**(2):191-193, 2003
158. Lamprecht P et al: Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). *Ann Rheum Dis* **63**(11):1518-1520, 2004

159. Gattorno M et al: Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. *Arthritis Rheum* **58**(5):1516-1520, 2008
160. Sacre K et al: Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. *J Rheumatol* **35**(2):357-358, 2008
161. Blau EB: Familial granulomatous arthritis, iritis, and eruption. *J Pediatr* **107**(5):689-693, 1985
162. Jabs DA et al: Familial granulomatous synovitis, uveitis, and cranial neuropathies. *Am J Med* **78**(5):801-804, 1985
163. Rose C.D et al: Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. *J Rheumatol* **32**(2):373-375, 2005
164. Rose CD et al: NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: Study of an international registry and a national cohort in Spain. *Arthritis Rheum* **60**(6):1797-1803, 2009
165. Becker ML, Rose CD: Blau syndrome and related genetic disorders causing childhood arthritis. *Curr Rheumatol Rep* **7**(6):427-433, 2005
166. Hetherington S: Sarcoidosis in young children. *Am J Dis Child* **136**(1):13-15, 1982
167. Inohara N, Nunez G: NODs: Intracellular proteins involved in inflammation and apoptosis. *Nat Rev Immunol* **3**(5):371-382, 2003
168. Creagh EM, O'Neill LA: TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity. *Trends Immunol* **27**(8):352-357, 2006
169. Priori R et al: Sporadic Blau syndrome with a double CARD15 mutation. Report of a case with lifelong follow-up. *Sarcoidosis Vasc Diffuse Lung Dis* **21**(3):228-231, 2004
170. Rose CD et al: Pediatric granulomatous arthritis: An international registry. *Arthritis Rheum* **54**(10):3337-3344, 2006
171. Arostegui JI et al: NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. *Arthritis Rheum* **56**(11):3805-3813, 2007
172. Tilly JJ, Drolet BA, Esterly NB: Lichenoid eruptions in children. *J Am Acad Dermatol* **51**(4):606-624, 2004
173. Kanazawa N, Furukawa F: Autoinflammatory syndromes with a dermatological perspective. *J Dermatol* **34**(9):601-618, 2007
174. Schaffer JV et al: Widespread granulomatous dermatitis of infancy: An early sign of Blau syndrome. *Arch Dermatol* **143**(3):386-391, 2007
175. Okafuji I et al: Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. *Arthritis Rheum* **60**(1):242-250, 2009
176. Milman N et al: Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. *APMIS* **114**(12):912-919, 2006
177. Yasui K et al: Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: Its possible action and mechanism. *Arthritis Rheum* **62**(1):250-257, 2010
178. Majeed HA et al: Congenital dyserythropoietic anemia and chronic recurrent multifocal osteomyelitis in three related children and the association with Sweet syndrome in two siblings. *J Pediatr* **115**(5 Pt 1):730-734
179. El-Shanti HI, Ferguson PJ: Chronic recurrent multifocal osteomyelitis: A concise review and genetic update. *Clin Orthop Relat Res* **462**:11-19, 2007
180. Moore KW et al: Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol* **19**:683-765, 2001
181. Kotenko SV et al: Identification and functional characterization of a second chain of the interleukin-10 receptor complex. *EMBO J* **16**(19):5894-5903, 1997
182. Kotenko SV et al: Identification of the functional interleukin-22 (IL-22) receptor complex: The IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. *J Biol Chem* **276**(4):2725-2732, 2001
183. Sheppard P et al: IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol* **4**(1):63-68, 2003
184. Kuhn R et al: Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* **75**(2):263-274, 1993

